-
2023-504630-22-00
7
2024-04-19
Non-Small Cell Lung Cancer
-
2023-507217-10-00
5
2024-04-12
Thyroid eye disease
-
2023-505414-15-00
4
2024-04-10
Dermatitis, Atopic
-
2022-501969-42-00
5
2024-03-28
Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criter
-
2023-506092-10-00
4
2024-03-11
Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous
-
2023-505543-39-00
5
2024-02-12
Chronic Obstructive Pulmonary Disease (COPD)
-
2023-507304-32-00
6
2024-02-09
Chronic Obstructive Pulmonary Disease
-
2023-503911-14-00
4
2024-01-25
Psoriasis
-
2023-505487-11-00
5
2023-12-21
Actinic Keratosis on the Face or Scalp
-
2023-503739-16-00
1
2023-12-20
Relapsed or refractory solid tumors or non-Hodgkin lymphoma
-
2022-503137-66-00
5
2023-11-29
Human immunodeficiency virus (HIV)
-
2022-502208-64-00
4
2023-11-25
Asthma
-
2023-503418-63-00
4
2023-11-23
Head and Neck Squamous Cell Carcinoma
-
2022-501418-69-00
5
2023-11-21
Acute Coronary Syndrome
-
2022-502880-39-00
4
2023-11-13
Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
-
2022-500777-14-00
4
2023-11-06
Atopic Dermatitis
-
2022-502476-23-00
4
2023-10-25
Treatment of immunotherapy-naive patients with previously untreated or
-
2022-501074-19-00
10
2023-10-13
Hidradenitis suppurativa
-
2024-512767-30-00
4
2023-09-28
Eosinophilic Esophagitis
-
2022-502174-16-00
5
2023-09-13
Macular edema secondary to retinal vein occlusion
-
2022-502546-26-00
3
2023-09-11
Sickle Cell Disease
-
2022-502647-35-00
4
2023-09-01
Non-alcoholic steatohepatitis
-
2022-500746-16-00
4
2023-08-11
Geographic Atrophy
-
2023-508267-69-00
3
2023-08-11
Subjects with Aadvanced solid tumors for whom life-prolonging therapie